SPIRARE II Post Hoc Analyses Presented for Jupiter Endovascular’s Vertex Thrombectomy System

November 3, 2026—Jupiter Endovascular, Inc., announced findings from post hoc analyses of its SPIRARE II pivotal trial examining pulmonary artery (PA) pressure and right ventricular (RV) recovery after treatment with the company’s Vertex thrombectomy system for pulmonary embolism (PE). The findings were presented at TCT 2026 by Sripal Bangalore, MD, MHA, Professor of Medicine at NYU Grossman School of Medicine.

According to the company, mean PA pressure decreased in 93% of patients treated with the Vertex system, and half had mean PA pressure within the normal range (≤ 20 mm Hg) at the end of the procedure. Patients whose pressures normalized were more likely to demonstrate RV recovery at 48 hours, as assessed by RV-PA coupling.

The analysis also found that accessing more vessels, including those in the lower lung lobes, was associated with a greater likelihood of pressure normalization. The company noted that, although exploratory, these findings suggest that the lower lobes may be an important target for restoring normal hemodynamics.

“What stands out is that an intraprocedural normalization of mean PA pressure is one of the indicators of how well the right ventricle functions 2 days later,” commented Dr. Bangalore in the company’s press release. “It also raises an important question for our field about how complete we should be with clot removal, including targeting the lower lobes, and how that shapes a patient’s recovery.”

The prospective, single-arm, multicenter SPIRARE II trial enrolled 123 patients treated by 33 interventionalists at 19 sites in the United States and Europe. Investigators used invasive right heart catheterization to measure pressures before and immediately after treatment in all patients. Echocardiographic assessments of RV function at baseline and 48 hours were evaluated by an independent core laboratory.

Previously reported findings showed an average reduction in mean PA pressure of 8.5 mm Hg (29%) immediately after treatment. According to the company, the trial met its primary effectiveness endpoint of RV/left ventricular ratio reduction at 48 hours and its primary safety endpoint assessing major adverse events at 48 hours. Full results were published by Sayfo et al in EuroIntervention.

The Vertex system incorporates Jupiter’s Transforming Fixation (TFX) technology, which allows the catheter to remain flexible during navigation and stabilize within the PAs during treatment. According to the company, the design enables operators to redirect the catheter between lobes without repeatedly crossing the pulmonic valve.

The Vertex thrombectomy system is indicated for use in the PAs for the nonsurgical removal of emboli and thrombi and the injection, infusion, and/or aspiration of contrast media and other fluids. It is intended for the treatment of PE.